Refine by
Applications
- Clinical Immunology and Intensive Care Medicine for Haemophilia
- Clinical Immunology and Intensive Care Medicine for Immunoglobulins
- Clinical Immunology and Intensive Care Medicine for Antibody Deficiency
- Drug Dolution for Liver Metastases
- Drug Dolution for Gastric Cancer
- Microbiome Therapeutics for Clinical Trials
- Microbiome Therapeutics for Patients and Physicians
- Solution for Ultrafast Laser Spectroscopy / Imaging
- Solution for High-Speed 4D Imaging
Clinical Development Equipment & Supplies In Chile
131 equipment items found
Manufactured by:Frontier Biotechnologies Inc. based inNanjing, CHINA
FB2001 (generic name: Bofutrelvir) is a SARS-CoV-2 3CL protease inhibitor under clinical development for hospitalized patients as well as for post-exposure prophylaxis of Covid-19. It is a peptidomimetic compound targeting 3CL-protease based on three-dimensional crystal structure of the protease. Preclinical data has shown it has potent activities in vitro and in ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
A randomized, double-blind, placebo-controlled, single and repeated dose, escalation clinical trial to evaluate the safety, tolerability, and pharmacokinetics of VVZ-149 injection in healthy adult ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
Single-dose, escalation clinical trial to evaluate the safety and pharmacokinetics of VVZ-149 injection in healthy elderly ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
A randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the analgesic efficacy and safety of VVZ-149 Injection in patients who have pain after laparoscopic gastrectomy in early gastric cancer ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
A Randomized, double-blind, parallel group, placebo-controlled study to evaluate the analgesic efficacy and safety of VVZ-149 injections for post-operative pain following laparoscopic colorectal ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
A randomized, double-blind, parallel-group, placebo-controlled clinical trial to evaluate the analgesic efficacy and safety of VVZ-149 Injection in patients who have pain after laparoscopic and robotic-laparoscopic ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
A multicenter, randomized, double-blind, parallel-group, placebo-controlled phase 3 clinical trial to evaluate the analgesic efficacy and safety of VVZ-149 injection in patients who have pain after laparoscopic ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
A randomized, double-blind, parallel group, placebo-controlled clinical trial to evaluate the analgesic efficacy and safety of VVZ-149 Injection in patients who have pain after artificial hip replacement ...
by:Vivozon Inc. based inYongin-si, SOUTH KOREA
Analgesic efficacy and safety of VVZ-149 injections for post-operative pain following laparoscopic colorectal surgery: a randomized, double-blind, parallel group, placebo-controlled, dose finding ...
Manufactured by:Ariana Pharma based inParis, FRANCE
Ariana® has consolidated multiple, publicly available administrative healthcare admissions databases into a locally searchable observational health data resource of patient hospitalization, outpatient and other episodes, comprising in excess of 6B records. ...
Manufactured by:EsoCap AG based inBasel, SWITZERLAND
EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for targeted and long-lasting treatment of diseases of the upper gastrointestinal tract for the first ...
Manufactured by:Creative Peptides based inNew York, NEW YORK (USA)
Abaloparatide is a parathyroid hormone-related protein (PTHrP) analog drug in clinical development for treating osteoporosis. Like the related drug teriparatide, and unlike bisphosphonates, it is an anabolic (i.e., bone growing) agent.https://www.creative-peptides.com/product/abaloparatide-item-10-101-172-33658.html ...
Manufactured by:Aurinia Pharmaceuticals Inc. based inVictoria, BRITISH COLUMBIA (CANADA)
BAFF and APRIL promote B cell survival and differentiation and have been shown to play a prominent role in the pathogenesis of certain autoimmune and nephrology conditions. AUR200 is currently undergoing pre-clinical development with projected submission of an IND to the FDA in ...
Manufactured by:Aurinia Pharmaceuticals Inc. based inVictoria, BRITISH COLUMBIA (CANADA)
Dysregulation of M2 macrophages drives fibrosis. AUR300 acts to reduce M2 dysregulation and decrease inflammatory cytokines, and therefore may have significant clinical applications for autoimmune and fibrotic diseases. It is anticipated that clinical development for AUR300 will commence during the first half of ...
Manufactured by:Catalent, Inc based inSomerset, NEW JERSEY (USA)
Antibody-drug conjugates (ADCs) combine the targeted binding specificity and pharmacological advantages of monoclonal antibodies with the potency advantages of small molecule chemotherapy agents via conjugation with chemical linkers. With 10 approved products and a large and growing list of programs in clinical and pre-clinical development, ADCs ...
Manufactured by:Biotest AG based inDreieich, GERMANY
Trimodulin mediates its mode of action via three potential mechanisms which are; opsonization of causal pathogens, neutralizing of microbial pathogens and their virulence factors (endo- and exotoxins) and targeting the host inflammatory response (anti-inflammatory properties). Currently, trimodulin is under clinical development for severe community-acquired ...
Manufactured by:Gesynta Pharma AB based inStockholm, SWEDEN
GS-248 is Gesynta Pharma’s most advanced drug candidate, currently in clinical development as a potential treatment of systemic sclerosis. Recent clinical phase I data in healthy individuals show that GS-248 potently inhibits the production of PGE2 in a tolerable and safe manner, while increasing the observed levels of protective and ...
Manufactured by:Frontier Biotechnologies Inc. based inNanjing, CHINA
Licensed with exclusive rights for greater China from AFFiRiS AG, a clinical-stage biotechnology company in Austria, FB6001 is an investigational therapeutic peptide vaccine targeting PCSK9 to treat hypercholesterolemia. PCSK9 is a clinically validated target and FB6001 is a potential first-in-class immunotherapy for hypercholesteremia. FB6001 is expected to be ...
Manufactured by:Finch Therapeutics Group, Inc. based inSomerville, MASSACHUSETTS (USA)
CP101, an orally administered, Complete Consortia product candidate in late-stage clinical development for the prevention of recurrent C. difficile infection is also being developed for the treatment of chronic HBV. Chronic HBV infection occurs when the initial immune response fails to clear the virus, and may result in inflammation of ...
Manufactured by:MorphoSys AG based inPlanegg, GERMANY
Preclinical studies and translational insights from our first-in-human study of pelabresib led us to prioritize the clinical development of pelabresib in ...